Clinical trials in gastric cancer and the future

Journal of Surgical Oncology

Volumn 107, Issue 3, 2013, Pages 289-297

  Mihaljevic, André L ^a   Friess, Helmut ^a   Schuhmacher, Christoph ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

clinical trials; gastric cancer; multimodality therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; PANITUMUMAB; TRASTUZUMAB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; GASTRECTOMY; GASTRECTOMY BILLROTH II; GASTROJEJUNOSTOMY; HUMAN; LYMPH NODE DISSECTION; MULTICENTER STUDY (TOPIC); MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; ROUX Y ANASTOMOSIS; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; STOMACH NEOPLASMS;

EID: 84873406666     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23120     Document Type: Review

References (90)

1. Woelfler A,: Über die von Herrn Professor Billroth ausgeführten resectionen des carcinomatösen Pylorus. Wien med Wschr 1881; 31: 14-27.
2. Schlatter C,: Vollständige Entfernung des Magens, Ösophagoenterostomie beim Mensch. Beitr Klin Chir 1897; 19: 757.
3. Ian M,: Pauchet's method of gastrectomy. Lancet 1920; 195: 308-310.
4. Hunt CJ,: Malignant disease of the stomach: Modified technique for total gastrectomy. J Int Coll Surg 1952; 18: 651-660.
5. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Available at:
6. SEER Cancer Statistics Review.1975-2008. Available at:
7. Fock KM, Talley N, Moayyedi P, et al.: Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-365.
8. Scottish intercollegiate guidelines network management of oesophageal and gastric cancer. A Natl Clin Guideline 2008; 87: 757-776.
9. Moehler M, Al-Batran S-E, Andus T, et al.: German S3-guideline "diagnosis and treatment of esophagogastric cancer. " Z Gastroenterol 2011; 49: 461-531.
10. Barbour AP, Rizk NP, Gerdes H, et al.: Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg 2007; 205: 593-601.
11. Oldenburg A, Albrecht T,: Baseline and contrast-enhanced ultrasound of the liver in tumor patients. Ultraschall Med 2008; 29: 488-498.
12. Piscaglia F, Corradi F, Mancini M, et al.: Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer 2007; 7: 171-181.
13. Dietrich CF, Kratzer W, Strobe D, et al.: Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12: 1699-1705.
14. Albrecht T, Blomley MJK, Burns PN, et al.: Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: Multicenter study. Radiology 2003; 227: 361-370.
15. Ott K, Lordick F, Blank S, et al.: Gastric cancer: Surgery in 2011. Langenbecks Arch Surg 2011; 396: 743-758.
16. Kinkel K, Lu Y, Both M, et al.: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002; 224: 748-756.
17. Ott K, Lordick F, Herrmann K, et al.: The new credo: Induction chemotherapy in locally advanced gastric cancer: Consequences for surgical strategies. Gastric Cancer 2008; 11: 1-9.
18. Mukai K, Ishida Y, Okajima K, et al.: Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006; 9: 192-196.
19. Yoshioka T, Yamaguchi K, Kubota K, et al.: Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003; 44: 690-699.
20. Kwee RM, Kwee TC,: Imaging in local staging of gastric cancer: A systematic review. J Clin Oncol 2007; 25: 2107-2116.
21. Puli S-R, Batapati Krishna Reddy J, Bechtold ML, et al.: How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review. World J Gastroenterol 2008; 14: 4011-4019.
22. Stein HJ, Feith M, Siewert JR,: Cancer of the esophagogastric junction. Surg Oncol 2000; 9: 35-41.
23. Chen VK, Eloubeidi MA,: Endoscopic ultrasound-guided fine needle aspiration is superior to lymph node echofeatures: A prospective evaluation of mediastinal and peri-intestinal lymphadenopathy. Am J Gastroenterol 2004; 99: 628-633.
24. Power DG, Schattner MA, Gerdes H, et al.: Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 2009; 208: 173-178.
25. Ychou M, Gory-Delabaere G, Blanc P, et al.: Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach-radiotherapy. Cancer Radiother 2004; 8: 322-335.
26. Ryu KW, Eom BW, Nam B-H, et al.: Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? A meta-analysis of feasibility studies. J Surg Oncol 2011; 104: 578-584.
27. Cardoso R, Bocicariu A, Dixon M, et al.: What is the accuracy of sentinel lymph node biopsy for gastric cancer? A systematic review. Gastric Cancer 2012; [Epub ahead of print] DOI: 10.1007/s10120-011-0103-8
28. Wang Z, Dong Z-Y, Chen J-Q, et al.: Diagnostic value of sentinel lymph node biopsy in gastric cancer: A meta-analysis. Ann Surg Oncol 2011; [Epub ahead of print] DOI: 10.1245/s10434-011-2124-2
29. Lee SE, Lee JH, Ryu KW, et al.: Sentinel node mapping and skip metastases in patients with early gastric cancer. Ann Surg Oncol 2009; 16: 603-608.
30. Siewert JR, Sendler A,: Potential and futility of sentinel node detection for gastric cancer. Recent Results Cancer Res 2000; 157: 259-269.
31. Yang H-K,: Sentinel node biopsy in early gastric cancer: Constant exertion for clinical application. Ann Surg Oncol 2011; 19: 353-354.
32. Kajitani T,: The general rules for the gastric cancer study in surgery and pathology. Part I: Clinical classification. Jpn J Surg 1981; 11: 127-139.
33. Japanese gastric cancer association Japanese classification of gastric carcinoma-2nd English Edition. Gastric Cancer 1998; 1: 10-24.
34. Sobin LH, Wittekind C,: TNM classification of malignant tumours. New York: John Wiley & Sons; 1997.
35. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123.
36. Robertson CS, Chung SC, Woods SD, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220: 176-182.
37. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-748.
38. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-999.
39. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
40. Songun I, Putter H, Kranenbarg EM-K, et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
41. Hartgrink HH, van de Velde CJH, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077.
42. Degiuli M, Sasako M, Ponti A, et al.: Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer study group prospective multicenter surgical study. J Clin Oncol 1998; 16: 1490-1493.
43. Degiuli M, Sasako M, Ponti A,: Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010; 97: 643-649.
44. Birkmeyer JD, Sun Y, Wong SL, et al.: Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245: 777-783.
45. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
46. Yonemura Y, Wu C-C, Fukushima N, et al.: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008; 13: 132-137.
47. Yonemura Y, Wu CC, Fukushima N, et al.: Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: A prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology 2006; 53: 389-394.
48. Kulig J, Popiela T, Kolodziejczyk P, et al.: Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: An interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193: 10-15.
49. Chen X-Z, Hu J-K, Zhou Z-G, et al.: Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. J Am Coll Surg 2010; 210: 100-105.
50. Wang Z, Chen J-Q, Cao Y-F,: Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer. World J Gastroenterol 2010; 16: 1138-1149.
51. Hölscher AH, Drebber U, Mönig SP, et al.: Early gastric cancer: Lymph node metastasis starts with deep mucosal infiltration. Ann Surg 2009; 250: 791-797.
52. Soetikno R, Kaltenbach T, Yeh R, et al.: Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005; 23: 4490-4498.
53. Isomoto H, Shikuwa S, Yamaguchi N, et al.: Endoscopic submucosal dissection for early gastric cancer: A large-scale feasibility study. Gut 2009; 58: 331-336.
54. Yamaguchi N, Isomoto H, Fukuda E, et al.: Clinical outcomes of endoscopic submucosal dissection for early gastric cancer by indication criteria. Digestion 2009; 80: 173-181.
55. Hitomi G, Watanabe H, Tominaga K, et al.: Endoscopic submucosal dissection in 100 lesions with early gastric carcinoma. Hepatogastroenterology 2009; 56: 254-260.
56. Gotoda T, Iwasaki M, Kusano C, et al.: Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010; 97: 868-871.
57. Yokoi C, Gotoda T, Hamanaka H, et al.: Endoscopic submucosal dissection allows curative resection of locally recurrent early gastric cancer after prior endoscopic mucosal resection. Gastrointest Endosc 2006; 64: 212-218.
58. Oda I, Gotoda T, Sasako M, et al.: Treatment strategy after non-curative endoscopic resection of early gastric cancer. Br J Surg 2008; 95: 1495-1500.
59. Ishikawa S, Togashi A, Inoue M, et al.: Indications for EMR/ESD in cases of early gastric cancer: Relationship between histological type, depth of wall invasion, and lymph node metastasis. Gastric Cancer 2007; 10: 35-38.
60. Song K-Y, Park S-M, Kim S-N, et al.: The role of surgery in the treatment of recurrent gastric cancer. Am JSurg 2008; 196: 19-22.
61. Bennett C, Wang Y, Pan T,: Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev 2009; Art. No.: CD004276. DOI: 10.1002/14651858.CD004276.pub3
62. Oda I, Saito D, Tada M, et al.: A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 2006; 9: 262-270.
63. Watanabe K, Ogata S, Kawazoe S, et al.: Clinical outcomes of EMR for gastric tumors: historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection. Gastrointest. Endosc 2006; 63: 776-782.
64. Ishihara R, Iishi H, Uedo N, et al.: Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest. Endosc 2008; 68: 1066-1072.
65. Uedo N, Iishi H, Tatsuta M, et al.: Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006; 9: 88-92.
66. Moertel CG, Childs DS, O'Fallon JR, et al.: Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J. Clin. Oncol 1984; 2: 1249-1254.
67. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med 2001; 345: 725-730.
68. Kim S, Lim DH, Lee J, et al.: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int. J. Radiat. Oncol. Biol. Phys 2005; 63: 1279-1285.
69. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med 2007; 357: 1810-1820.
70. Ajani JA, Rodriguez W, Bodoky G, et al.: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol 2010; 28: 1547-1553.
71. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol 1993; 11: 1441-1447.
72. Panzini I, Gianni L, Fattori PP, et al.: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-27.
73. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol 2000; 11: 837-843.
74. Janunger K-G, Hafström L, Glimelius B,: Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168: 597-608.
75. Paoletti X, Oba K, Burzykowski T, et al.: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010; 303: 1729-1737.
76. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med 2006; 355: 11-20.
77. Ychou M, Boige V, Pignon J-P, et al.: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol 2011; 29: 1715-1721.
78. Schuhmacher C, Gretschel S, Lordick F, et al.: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J. Clin. Oncol 2010; 28: 5210-5218.
79. Kim H-H, Hyung WJ, Cho GS, et al.: Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer. Ann Surg 2010; 251: 417-420.
80. Park DJ, Han S-U,., Hyung WJ, et al.: Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective study. Surg Endosc 2011. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22170319. Accessed March 8, 2012.
81. Bang Y-J, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
82. Okines AF, Langley R, Cafferty FH, et al.: Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin, plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol 2010; 28: suppl; abstr 4019.
83. Lowy AM, Mansfield PF, Leach SD, et al.: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann. Surg 1999; 229: 303-308.
84. Shah MA, Yeung H, Coit D, et al.: A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer(NCI 5917): FDG-PET/CT predicts patient outcome. J Clin Oncol 2007; 28: 4502.
85. Lordick F, Ott K, Krause B-J, et al.: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
86. zum Büschenfelde CM, Herrmann K, Schuster T, et al.: (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial. J Nucl Med 2011; 52: 1189-1196.
87. Parsons S, Murawa PX, Koralewski P, et al.: Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study. J Clin Oncol 2008; 26: abst 3000.
88. Siewert JR, Stein HJ, Sendler A, et al.: Surgical resection for cancer of the cardia. Semin Surg Oncol 1999; 17: 125-131.
89. Barbour AP, Rizk NP, Gonen M, et al.: Adenocarcinoma of the gastroesophageal junction: Influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007; 246: 1-8.
90. Sasako M, Sano T, Yamamoto S, et al.: Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: A randomised controlled trial. Lancet Oncol 2006; 7: 644-651.